Seroquel Sales Aid Cited By FDA For Minimizing Diabetes Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca’s material “undermines” class hyperglycemia and diabetes warnings from the atypical antipsychotic’s label, FDA says.
You may also be interested in...
Antipsychotic Marketing Investigation Broadens
Pfizer and Lilly join AstraZenenca under California attorney general’s microscope for marketing practices related to antipsychotics.
Lilly To Pay Up To $690 Mil. To Settle Majority Of Zyprexa Injury Claims
Settlement will cover approximately 8,000 personal injury claims regarding diabetes and hyperglycemia, or about 75% of the total number of cases, Lilly says. “Lilly is prepared to continue its vigorous defense of Zyprexa in the remaining cases,” the company said.
Lilly Zyprexa "Dear Doctor" Letter Warns Of Diabetes Risk
The letter notes that FDA has requested an atypical antipsychotics class warning describing the increased risk of hyperglycemia and diabetes.